Therapy Areas: Autoimmune
European Commission approves RINVOQ for severe alopecia areata
29 July 2026 - US biopharmaceutical company AbbVie (NYSE: ABBV) said on Wednesday it has received European Commission approval for RINVOQ (upadacitinib) to treat adults and adolescents aged 12 and ove...
AbCellera and Vertex agree collaboration to develop multispecific T-cell engagers
29 July 2026 - Clinical-stage biotechnology company AbCellera Biologics Inc (Nasdaq:ABCL) announced on Wednesday that it has entered into a collaboration with biopharmaceutical company Vertex Pharmace...
AbelZeta's C-CAR168 registrational Phase II trial in refractory Lupus Nephritis granted FDA clearance
28 July 2026 - Clinical-stage biopharmaceutical company AbelZeta Pharma Inc announced on Monday the receipt of US Food and Drug Administration (FDA) clearance under its Regenerative Medicine Advanced ...
argenx agrees to acquire Forte Biosciences for USD2.2bn to add anti-CD122 antibody FB102
27 July 2026 - Immunology innovation company argenx (Euronext & Nasdaq: ARGX) disclosed on Monday that it has entered into a definitive agreement to acquire biopharmaceutical company Forte Bioscie...
AbelZeta's C-CAR168 receives EMA PRIME designation for Lupus Nephritis and Systemic Lupus Erythematosus
21 July 2026 - Clinical-stage biopharmaceutical company AbelZeta Pharma Inc announced on Monday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) ha...
Sareum completes dosing in Phase 2-enabling toxicology programme for SDC-1801
20 July 2026 - Biotechnology company Sareum Holdings plc (AIM: SAR) announced on Monday that it has completed dosing in the Phase 2-enabling toxicology programme for SDC-1801, its selective oral TYK2/...